Press Release Details

LAUSANNE, Switzerland, Nov. 14, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based biopharmaceutical company with a broad clinical-stage pipeline focused on neurodegenerative diseases, today announced that it will present at Jefferies 2019 London Healthcare Conference in London, UK, taking place November 20 – 21, 2019.

Prof. Andrea Pfeifer, Ph.D., CEO of AC Immune SA, will discuss the Company’s world-leading pipeline and Roadmap to Successful Therapies for Neurodegenerative Diseases, with a focus on its clinical programs targeting misfolded Tau protein. AC Immune is addressing the full spectrum of Tau pathology by detecting and inhibiting both early seeding and extracellular spreading of Tau with its internally discovered, best-in-class small molecule (Partner: Eli Lilly), antibody (Partner: Roche/Genentech) and vaccine (Partner: Janssen) therapies, as well as its highly specific Tau diagnostic agents (Partner: Life Molecular Imaging).

Jefferies 2019 London Healthcare Conference
Date: November 21, 2019 | 5:20 pm GMT
Format: Fireside chat
Presenter: Prof. Andrea Pfeifer, CEO, AC Immune

A webcast of the presentation will be available on the Events Page of AC Immune’s website and at the Jefferies 2018 Healthcare Conference website and will be active for 90 days following the event.

About AC Immune
AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in Precision Medicine for neurodegenerative diseases. The Company is utilizing two proprietary discovery platforms, SupraAntigen™ and Morphomer™, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins. The Company's pipeline features nine therapeutic and three diagnostic product candidates, with five currently in clinical trials. It has collaborations with major pharmaceutical companies including Roche/Genentech, Lilly and Janssen Pharmaceuticals Inc.

As a strategic leader in the field of neurodegenerative diseases, AC Immune has developed a five point Roadmap to Successful Therapies for Neurodegenerative Diseases that recognizes the importance of treating earlier, targeting Tau, focusing on more homogeneous populations, precision medicine and exploring neuroinflammation as a target.

For further information, please contact:

Forward-looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information—Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

Source: AC Immune SA